Denosumab

CHEMBL1237023 Phase 4 Disetujui Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A human monoclonal antibody that inhibits RANKL, a key mediator of osteoclast activity, thereby reducing bone breakdown; used to treat osteoporosis, bone metastases, and giant cell tumors of bone. At higher doses used for oncology indications it carries a risk of hypocalcemia and osteonecrosis of the jaw.

Area Terapeutik

Endocrinology Osteoporosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A human monoclonal antibody that inhibits RANKL, a key mediator of osteoclast activity, thereby reducing bone breakdown; used to treat osteoporosis, bone metastases, and giant cell tumors of bone. At higher doses used for oncology indications it carries a risk of hypocalcemia and osteonecrosis of the jaw.

Yes, Denosumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1237023. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Mencari informasi yang ramah bagi pasien?

Denosumab di PillFYI

Data Cepat

Sinonim: 17

Tautan Eksternal

ChEMBL CHEMBL1237023

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.